Evidence map›Paper›PMID 30578357›Full record

ArticleCancer discovery2019

Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA.

Jonathan C Dudley, Joseph Schroers-Martin, Daniel V Lazzareschi, William Y Shi, Simon B Chen, Mohammad S Esfahani, Dharati Trivedi, Jacob J Chabon, Aadel A Chaudhuri, Henning Stehr and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 137 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
137citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

137 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

77 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jonathan C Dudley *Department of Pathology, Stanford University, Stanford, California.
Joseph Schroers-Martin *Department of Medicine, Stanford University, Stanford, California.
Daniel V LazzareschiDepartment of Pathology, Stanford University, Stanford, California.
William Y ShiDepartment of Pathology, Stanford University, Stanford, California.
Simon B ChenDepartment of Pathology, Stanford University, Stanford, California.
Mohammad S EsfahaniStanford Cancer Institute, Stanford University, Stanford, California.
Dharati TrivediDepartment of Urology, Stanford University, Stanford, California.
Jacob J ChabonStanford Cancer Institute, Stanford University, Stanford, California.
Aadel A ChaudhuriStanford Cancer Institute, Stanford University, Stanford, California.
Henning StehrDepartment of Pathology, Stanford University, Stanford, California.
Chih Long LiuDepartment of Medicine, Stanford University, Stanford, California.
Harumi LimDepartment of Pathology, Stanford University, Stanford, California.
Helio A CostaDepartment of Pathology, Stanford University, Stanford, California.
Barzin Y NabetStanford Cancer Institute, Stanford University, Stanford, California.ORCID 0000-0002-4824-3533
Mandy L Y SinCepheid, Sunnyvale, California.
Joseph C LiaoStanford Cancer Institute, Stanford University, Stanford, California.
Ash A AlizadehDepartment of Medicine, Stanford University, Stanford, California. diehn@stanford.edu arasha@stanford.edu.ORCID 0000-0002-5153-5625
Maximilian DiehnStanford Cancer Institute, Stanford University, Stanford, California. diehn@stanford.edu arasha@stanford.edu.

Funding

Modeling the Molecular Determinants of Induced Anti-Tumor Immune Responses in Mantle Cell LymphomaU01CA194389 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DAVIS, MARK MORRIS · 2015 to 2019
$3.1M
Developing a genomic approach for cancer screeningDP2CA186569 · NCI · STANFORD UNIVERSITY · PI DIEHN, MAXIMILIAN · 2013 to 2013
$2.4M
Cancer Systems Biology Scholars ProgramR25CA180993 · NCI · STANFORD UNIVERSITY · PI PLEVRITIS, SYLVIA KATINA · 2014 to 2018
$2.2M
Noninvasive monitoring of lung cancer patients treated with radiotherapyR01CA188298 · NCI · STANFORD UNIVERSITY · PI ALIZADEH, ASH ARASH, DIEHN, MAXIMILIAN · 2015 to 2019
$1.8M
High-throughput sequencer for multi-scale genomic studiesS10OD020141 · OD · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2015 to 2015
$600k
NCI NIH HHS DP2 CA186569NCI NIH HHS R01 CA188298NCI NIH HHS R25 CA180993NCI NIH HHS U01 CA194389NIH HHS S10 OD020141
6 · The paper itself

Abstract

Current regimens for the detection and surveillance of bladder cancer are invasive and have suboptimal sensitivity. Here, we present a novel high-throughput sequencing (HTS) method for detection of urine tumor DNA (utDNA) called utDNA CAPP-Seq (uCAPP-Seq) and apply it to 67 healthy adults and 118 patients with early-stage bladder cancer who had urine collected either prior to treatment or during surveillance. Using this targeted sequencing approach, we detected a median of 6 mutations per patient with bladder cancer and observed surprisingly frequent mutations of the

Indexed as

Biomarkers, TumorDNA, NeoplasmFemaleHumansMaleUrinary Bladder NeoplasmsBiomarkers, TumorDNA, Neoplasm

Identifiers

PMID30578357
PMCPMC6467650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.